Clinical Trial Update: Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability and pharmacokinetics of escalating doses of LPM3770164 in healthy subjects, with potential relevance to tardive dys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease
• Tardive Dyskinesia

Drugs mentioned

• LPM3770164

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Tardive Dyskinesia, Huntington Disease | Phase 1 | Status: COMPLETED